Polyendrogenic metabolic syndrome

Reading File

Finding Sources

Searching PubMed

polyendocrine metabolic syndrome

Reading Article

Searching the Web

polyendocrine metabolic ovarian syndrome PMOS new name PCOS 2026 Lancet

Finding Sources

Reading Web Page

PMOS polyendocrine metabolic ovarian syndrome diagnosis features pathophysiology treatment

Reading File

I now have comprehensive information to give a thorough answer. Let me compile everything.

Polyendocrine Metabolic Ovarian Syndrome (PMOS)

What Is It?

Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the official new name for what was previously called Polycystic Ovary Syndrome (PCOS). The rename was formalized in a landmark global consensus process published in The Lancet on June 6, 2026, led by Prof. Helena Teede of Monash University and endorsed by 56 international academic, clinical, and patient organizations - including the Endocrine Society, ASRM, and the International PCOS Network (effective May 12, 2026).

PMOS affects 1 in 8 women globally (~170 million women worldwide)
It is the most common endocrine disorder in reproductive-age women (10-13% prevalence)

Why the Name Was Changed

The old name "PCOS" was scientifically inaccurate for several reasons:

Problem with "PCOS"	How "PMOS" fixes it
Implies pathological ovarian cysts	The "cysts" are immature follicles, not true cysts
Focuses on ovaries alone	Captures multisystem endocrine + metabolic dysfunction
Led to delayed diagnosis (no cysts = missed diagnosis)	Shifts focus to core driving features
Contributed to stigma and fragmented care	Frames it as a whole-body metabolic-endocrine disorder
Curtailed research and policy framing	Enables broader research agenda

The name change process used iterative global surveys (14,360 patient responses), modified Delphi methods, and nominal group technique workshops. The consensus principles prioritized: scientific accuracy, clarity, stigma avoidance, cultural appropriateness, and implementation feasibility. - [Teede et al., Lancet 2026, PMID 42119588]

Pathophysiology

PMOS is a chronic, multisystem condition driven by genetic, epigenetic, and lifestyle factors. The central pathophysiological drivers are:

Core Hormonal/Metabolic Abnormalities

Hyperandrogenism - elevated androgens (testosterone, DHEA-S, androstenedione)
- Androgens directly upregulate hepatic lipogenic gene expression
- Activate hepatic stellate cells via androgen receptor signaling
- Suppress sex hormone-binding globulin (SHBG), worsening free androgen excess
Hyperinsulinemia / Insulin resistance - present in the majority; worsens androgenism and ovarian dysfunction
Dysregulation of the hypothalamic-pituitary-ovarian axis - elevated LH pulse frequency, elevated LH:FSH ratio
Chronic low-grade inflammation
Adipose tissue dysfunction and adipokine dysregulation

Overweight and obesity amplify all of these mechanisms.

Clinical Features

Reproductive

Irregular or absent menstrual cycles (oligomenorrhea/amenorrhea)
Anovulation and subfertility
Polycystic ovarian morphology on ultrasound (multiple small follicles - NOT true cysts)
Endometrial abnormalities
Increased risk of miscarriage

Hyperandrogenic

Hirsutism (excess facial/body hair)
Acne
Androgenic alopecia (scalp hair thinning)

Metabolic

Insulin resistance and hyperinsulinemia
Obesity (especially central/visceral adiposity)
Dyslipidemia (elevated LDL, low HDL, elevated triglycerides)
Impaired glucose tolerance / Type 2 diabetes
Metabolic dysfunction-associated steatotic liver disease (MASLD) - shared pathophysiology via androgen-driven hepatic lipogenesis and mitochondrial impairment
Hypertension and increased cardiovascular risk

Psychological

Increased rates of depression and anxiety
Body image concerns
Disordered eating

Diagnosis

PMOS remains a diagnosis of exclusion - other causes of similar symptoms must be ruled out first (thyroid disorders, adrenal disorders, hyperprolactinemia, Cushing syndrome, congenital adrenal hyperplasia, androgen-secreting tumors).

The Rotterdam 2003 criteria (2 of 3 features required) remain the foundation for diagnosis:

Oligo/anovulation
Clinical and/or biochemical hyperandrogenism
Polycystic ovarian morphology on ultrasound

Once diagnosed, all patients should be screened for: obesity, hypertension, glycemic control (fasting glucose/HbA1c), depression, and anxiety. Overweight/obese patients should also have a fasting lipid profile.

Pregnancy Complications

PMOS carries "higher-risk" status in pregnancy per the 2023 international evidence-based guidelines:

Early miscarriage
Gestational diabetes
Gestational hypertension
Preeclampsia
Preterm birth

These risks are exacerbated by the high prevalence of pre-pregnancy overweight/obesity and increased gestational weight gain. - [Teede et al., Nature Reviews Endocrinology 2026, PMID 42249166]

Management

Lifestyle (all patients)

Dietary modification and physical activity - first-line for all
Weight loss of even 5-10% significantly improves metabolic and reproductive outcomes

Hormonal/Reproductive (not seeking pregnancy)

Combined oral contraceptives (COCs) - first-line to regulate cycles and reduce androgens (via increased SHBG); lowest effective estrogen dose, cyclic or continuous
If inadequate response after 6 months: add antiandrogens (spironolactone, flutamide)
Endometrial protection: progestins (medroxyprogesterone acetate 10 mg or progesterone 200 mg for 10-14 days every 3 months) or levonorgestrel IUD

Ovulation Induction (seeking pregnancy)

Letrozole (aromatase inhibitor) - first-line for ovulation induction
Clomiphene citrate (SERM) ± metformin - second-line
Injectable gonadotropins - used judiciously due to risk of ovarian hyperstimulation syndrome

Metabolic

Metformin - considered for prevention of cardiometabolic risk in overweight/obese; adjunct with diet/exercise; treatment of impaired glucose tolerance or diabetes
Note: Metformin alone is NOT recommended for endometrial protection, hyperandrogenic symptoms, infertility, prevention of pregnancy loss, or gestational diabetes prevention
GLP-1 receptor agonists and other obesity medications are being studied for multisystem benefits in PMOS

Across the Female Lifespan

Critical vulnerability windows include adolescence, pregnancy, and menopause - each representing a period where hormonal transitions interact with PMOS pathophysiology to amplify cardiometabolic and liver-related risk. - [Stener-Victorin et al., Diabetologia 2026, PMID 42249186]

Implementation of the New Name

The transition from PCOS to PMOS is designed as evolution, not transformation:

A transition period is underway with dual terminology being used
ICD and disease classification systems are being updated
Patient education materials are being redesigned globally
Research organizations (NIH, etc.) are updating grant terminology

The abbreviation PMOS is the formal preferred term going forward, though PCOS will remain recognized during the transition period.

Key References:

Teede HJ et al. "Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process." Lancet. 2026. PMID 42119588
Teede HJ et al. "Polyendocrine metabolic ovarian syndrome in pregnancy: pathophysiology and outcomes." Nat Rev Endocrinol. 2026. PMID 42249166
Stener-Victorin E et al. "MASLD, diabetes and PMOS across the female life stages." Diabetologia. 2026. PMID 42249186
Harrison's Principles of Internal Medicine 22E (2025), Management of PCOS/PMOS, p.3179
Goldman-Cecil Medicine, Chapter on PCOS/PMOS

This is a shared conversation. Sign in to Orris to start your own chat.